Phase I/II clinical trial for therapeutic HB vaccine containing HBsAg and HBcAg
Not Applicable
- Conditions
- Chronic hepatitis B
- Registration Number
- JPRN-UMIN000027442
- Lead Sponsor
- Ehime University Graduate School of Medicine
- Brief Summary
The safety of HBsAg/HBcAg containing nasal administrative therapeutic vaccine. Anti-HBs induction and HBsAg reduction were confirmed after administration of the therapeutic vaccine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 71
Inclusion Criteria
Not provided
Exclusion Criteria
severe complication malignancy taking immunosuppresive agents
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety: frequency and degree of adverse events
- Secondary Outcome Measures
Name Time Method Efficacy: HBV-DNA reduction